B-FAST: Blood assay test for ALK-targeted therapy makes the grade in lung cancer
03 Oct 2019
byJairia Dela Cruz
Blood-first next-generation sequencing leads to identification of ALK fusions in patients with nonsmall cell lung cancer, which in turn guides treatment decision-making, according to the initial results of the phase II/III B-FAST* trial presented at the European Society for Medical Oncology (ESMO) Congress 2019.